Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
179 hedge funds and large institutions have $1.08B invested in Achillion Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 53 increasing their positions, 58 reducing their positions, and 26 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
96% more call options, than puts
Call options by funds: $126M | Put options by funds: $64.1M
85% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 26
40% more capital invested
Capital invested by funds: $770M → $1.08B (+$305M)
11% more funds holding
Funds holding: 161 → 179 (+18)
9% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$52.6M |
| 2 |
DM
Deerfield Management
New York
|
+$35.7M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$29M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$25.4M |
| 5 |
Goldman Sachs
New York
|
+$20.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$32.4M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$30.3M |
| 3 |
QF
QVT Financial
New York
|
-$24.3M |
| 4 |
Renaissance Technologies
New York
|
-$8.96M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$6.21M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SEC
201
Seven Eight Capital
New York
| – | -$94.2K | -9,443 | Closed |
|
|
BJ
202
BlackRock Japan
Tokyo,
Japan
| – | -$54K | -5,458 | Closed |
|
203
Parallax Volatility Advisers
San Francisco,
California
| – | -$55.7K | -4,558 | Closed |
|
|
RA
204
Royce & Associates
New York
| – | -$23K | -2,262 | Closed |
|
|
TDC
205
Thompson Davis & Co
Richmond,
Virginia
| – | -$2K | -250 | Closed |
|
ACHN Hedge Fund Activity: Q4 2014 in Review
179 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2014, worth a combined $1.08B — up 40% from $770M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new ACHN positions and 26 closed out — a net gain of 22 holders — while 53 added to existing stakes and 58 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $52.6M. The largest seller was Camber Capital Management, exiting entirely with an estimated $32.4M sold.
- 179 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2014, up from 161 in Q3 2014.
- Funds reported $1.08B of Achillion Pharmaceuticals stock for Q4 2014, up 40% quarter-over-quarter.
- 48 funds opened new Achillion Pharmaceuticals positions in Q4 2014 and 26 closed out, a net change of +22 holders.
- The largest Achillion Pharmaceuticals buyer in Q4 2014 was Fidelity Investments, an estimated $52.6M added.
- The largest Achillion Pharmaceuticals seller in Q4 2014 was Camber Capital Management, an estimated $32.4M sold.
Based on aggregated 13F filings for Q4 2014.